Healthy Returns: AbbVie is the newest potential weight loss drug market player
AbbVie will pay up to $2.2 billion to develop Danish drugmaker Gubra’s obesity drug. AI takes center stage at HIMSS ...
Zacks.com on MSN4h
Here's How to Play AbbVie Stock as it Enters the Obesity Space
Those who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth in 2025.
STAT21m
How the race for the next obesity drug is shaping up
While some drugs have fallen off, more have been added: AbbVie recently jumped into the obesity craze by licensing an ...
BioSpace8h
Tariff Threat Continues, More Meetings Cancelled, AbbVie Makes Obesity Play, More
Pfizer reacts to Donald Trump’s tariff threats on big pharma, another regulatory meeting is canceled under RFK Jr., AbbVie ...
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript March 4, 2025 Amylyx Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is ...
Tesla EV sales in China fell 49% in February
EV shipments in China tumbled in the month of February, plunging 49% year-over-year. Yahoo Finance senior autos reporter Pras ...
InnovationRx: Trump’s Tariffs Could Hit Medical Devices, While USAID Cuts Cost Lives
In this week’s InnovationRx newsletter, tariffs could hit medical devices, a gene therapy company that helps blind kids see ...
Wells Fargo Keeps Their Buy Rating on AbbVie (ABBV)
In a report released today, Mohit Bansal from Wells Fargo maintained a Buy rating on AbbVie (ABBV – Research Report), with a price target of ...